Sep 4, 2019

Multiple Myeloma Update — Part 4: Our interview with Dr Ghobrial highlights the following topics as well as cases from her practice:

• Case: A woman in her late 60s with high-risk R/R MM attains an excellent response to daratumumab/pomalidomide/dexamethasone (00:00)
• Evidence-based selection of up-front treatment combinations for younger versus older patients with newly diagnosed MM (01:36)
• Clinical significance of minimal residual disease (MRD) assessment; correlation between MRD negativity and long-term outcomes for patients with newly diagnosed MM receiving treatment (05:08)
• Selection, use and duration of maintenance therapy after ASCT (08:26)
• Significance of CHIP (clonal hematopoiesis of indeterminate potential) mutations and increased predisposition to hematologic cancer or cardiovascular-associated mortality (10:40)
• Therapeutic options for patients who experience disease progression on maintenance lenalidomide (13:52)
• Mechanisms of action of elotuzumab and daratumumab; activity and safety of immune-directed therapies for MM (15:47)
• Response and tolerability of anti-BCMA CAR T-cell therapies (18:25)
• Case: A man in his mid-50s with multiagent-refractory MM receives a BCMA-directed antibody-drug conjugate on a clinical trial (21:46)
• Case: A woman in her early 40s with high-risk smoldering MM with deletion 17p experiences a partial response to elotuzumab/lenalidomide/dexamethasone (24:26)
• Efficacy and cardiotoxicity with second-line carfilzomib/lenalidomide/dexamethasone followed by maintenance carfilzomib/lenalidomide for del(17p) smoldering MM (27:50)
• Activity of melflufen in patients with heavily pretreated MM (29:56)
• Newly approved and investigational approaches for heavily pretreated MM (31:47)
• Incidence of BRAF mutations in patients with MM; activity and ongoing investigation of BRAF inhibitors for R/R MM (33:25)

CME information and select publications